DPPIV inhibitors provide a potent treatment for T2DM by prolonging the activity of glucagon-like peptide 1 (GLP-1), improving insulin secretion, reducing blood glucose levels, and inhibiting the molecular pathways of insulin resistance [18]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.